Abstract
Introduction Non-atopic asthmatic patients generally have more severe clinical manifestations frequently accompanied by chronic sinusitis and nasal polyps, with more limited therapeutic options as compared to atopic asthmatic patients. This has led to a search for novel therapeutic approaches including omalizumab for non-atopic asthmatic patients who are not adequately controlled with current therapies.
Materials and Methods In this retrospective study undertaken between 1st August 2020 and 31st December 2021 at a tertiary allergy clinic, data from 61 non-atopic asthmatic patients inadequately controlled with optimum therapy was examined.
Results A total of 61 patients with severe asthma were included in the study [Female: 48 (78.7%), male: 13 (21.3%], mean age: 49 (18-71) years). The mean duration of asthma was 60 (18-160) months. A statistically significant increase in FEV1 (Forced expiratory volume in one second), FVC (forced vital capacity), and ACT (asthma control test) scores were found after 1 year of omalizumab treatment (p < 0.001, for all parameters). Omalizumab treatment was associated with a significant decrease in the number of asthma exacerbations, asthma-related hospitalization, duration of hospitalization, and the number of unplanned emergency room visits after 1 year (p < 0.001, for all parameters). One year treatment with omalizumab led to significant changes in eosinophil counts and serum IgE levels as well (p < 0.001 and p< 0.001)
Conclusion In the atopic severe asthma patient group omalizumab treatment provided similar clinical benefits to those observed in patients with severe atopic asthma, suggesting that it may be a useful therapeutic option in patients with non-atopic asthma who failed to benefit from step 4 and step 5 treatments.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Ethics Committee of Necmettin Erbakan University, Meram Faculty of Medicine (meeting date: January 21, 2022, and decision no: 2022/3608).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Informed consent The study protocol was approved by the Ethics Committee of Necmettin Erbakan University, Meram Faculty of Medicine (meeting date: January 21, 2022 and decision no: 2022/3608).
Funding source: No funding was secured for the study.
Financial disclosure: The authors have no financial relationship relevant to this article to disclose.
Conflict of interest: The authors have no conflicts of interest to disclose.
Disclaimers: None
Manuscripts that have not been presented orally or as a poster.
Data Availability
All data produced in the present study are available upon reasonable request to the authors